Place of New Generation Sulfonylurea: Gliclazide in the Evolving Landscape of Type 2 Diabetes Management

The management of Type 2 diabetes mellitus (T2DM) has evolved significantly, with a shift towards simplified dosing regimens and novel therapeutic agents. However, traditional medications like sulfonylureas, particularly the modern variant gliclazide, remain essential in managing T2DM, especially in resource-constrained settings. Gliclazide, a second-generation sulfonylurea, and its modified version Gliclazide MR is notable for its long-acting, once-daily formulation, better safety profile, and efficacy in lowering HbA1c levels, making it a preferred choice among sulfonylureas. It is effective in a broad patient population, including elderly individuals and those with chronic kidney disease, due to its minimal risk of hypoglycaemia and compatibility with renal impairment. Comparative studies also indicate that gliclazide has a lower risk of cardiovascular side effects relative to other sulfonylureas, as it selectively targets pancreatic SUR1 receptors without affecting cardiac receptors. Furthermore, its integration into fixed-dose combinations (FDCs) with other antidiabetic agents, such as metformin, supports adherence and helps achieve optimal glycemic control. As diabetes guidelines continue to emphasize individualized treatment, gliclazide is positioned as a promising, effective, and cost-efficient option, especially in countries like India where it addresses affordability and accessibility challenges. The findings underscore the importance of informing healthcare providers about gliclazide’s clinical utility, fostering its integration within T2DM treatment frameworks that balance efficacy, safety, and patient needs.